In vivo immunopotentiating activity of thymopentin in aging humans: increase of IL-2 production.
The effect of thymopentin (TP-5) treatment on lymphocyte immune functions has been investigated in immunocompromised aged subjects. TP-5 was able to improve the cutaneous delayed hypersensitivity (CDH) to recall antigens and the proliferative response to phytohemagglutinin (PHA), concanavalin A, and Pokeweed (PWM) as well as the PHA-induced interleukin-2 (Il-2) production. On the other hand, no detectable changes were induced by TP-5 treatment either on PWM-induced immunoglobulin synthesis or on lymphocyte subsets identified by monoclonal antibodies. Our results suggest that the enhancement of Il-2 synthesis might be a crucial mechanism of the immunopharmacological action of TP-5 in aging humans.
D000276:Adjuvants, Immunologic / Q000494:pharmacology* / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology; D005260:Female; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy / Q000276:immunology* / Q000378:metabolism; D007376:Interleukin-2 / Q000096:biosynthesis*; D037102:Lectins / Q000494:pharmacology; D008213:Lymphocyte Activation / Q000187:drug effects; D008214:Lymphocytes / Q000145:classification / Q000187:drug effects; D008297:Male; D010446:Peptide Fragments / Q000494:pharmacology* / Q000627:therapeutic use; D013268:Stimulation, Chemical; D016305:Thymopentin; D013946:Thymopoietins / Q000494:pharmacology* / Q000627:therapeutic use; D013951:Thymus Hormones / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D037102:Lectins; D010446:Peptide Fragments; D013946:Thymopoietins; D013951:Thymus Hormones; D016305:Thymopentin